



107 College Road East
 Princeton, NJ 08540
 Tel: 609.608.1246
 jcalvarez@drreddys.com

VIA EMAIL – AGO.highcostprescriptiondrugs@vermont.gov

May 9, 2023

Vermont Attorney General’s Office
 109 State Street
 Montpelier, VT 05609

RE: New Prescription Drug – 30-Day Notice

Dear Sir or Madam,

In accordance with 18 V.S.A. § 4637, Dr. Reddy’s Laboratories, Inc. provides the following notification:

NDC	Product Name	Size	WAC
43598064911	Treprostinil Injection 20 mg/20 mL (1 mg/mL)	20	\$ 1,145.99
43598064611	Treprostinil Injection 50 mg/20 mL (2.5 mg/mL)	20	\$ 2,864.97
43598064711	Treprostinil Injection 100 mg/20 mL (5 mg/mL)	20	\$ 5,729.94
43598064811	Treprostinil Injection 200 mg/20 mL (10 mg/mL)	20	\$11,459.88

Date of Introduction to Market:	04/20/2023
Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Treprostinil Injection 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), 200 mg/20 mL (10 mg/mL) (DRL ANDA 210214) is being marketed in the generic multi-source space. Establishing the WAC price for 20 mg/20 mL (1 mg/mL) at \$1,145.99, 50 mg/20 mL (2.5 mg/mL) at \$ 2,864.97, 100 mg/20 mL (5 mg/mL) at \$5,729.94 and 200 mg/20 mL (10 mg/mL) at \$11,459.88 constitutes a significant reduction in the WAC pricing of the referenced listed drug, Remodulin which, upon information and belief, was \$1,273.32 for 20 mg/20 mL (1 mg/mL), \$ 3,183.30 for 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL) for \$ 6,366.60 and \$12,733.20 for 200 mg/20 mL (10 mg/mL) at the time Dr. Reddy’s introduced Treprostinil Injection 20 mg/20 mL (1 mg/mL), 50 mg/20 mL (2.5 mg/mL), 100 mg/20 mL (5 mg/mL), 200 mg/20 mL (10 mg/mL) into the market, representing a 10% reduction in price. Dr. Reddy’s WAC pricing will enable it to: i) recoup the costs it incurred in evaluating the economic landscape surrounding prospective products; ii) cover distribution costs; iii) provide rebates and discounts as required by partners in the supply chain; and iv) earn a reasonable return on investment.

	Dr. Reddy's did not develop direct-to-consumer marketing or paid advertising for the product. In addition, we do not directly promote the product to physicians. To the extent that our purchasing agents or buyers are licensed pharmacists or HCPs we may provide them with product sell sheets which include product name, product description, available pack information, and order entry details. The spend on such materials is less than \$5,000 per year.
The estimated volume of patients that may be prescribed the drug	Dr. Reddy's does not track the estimated number of patients to be prescribed a drug on a monthly basis, due, among other reasons, to the fact that this is a generic product with numerous other generics available. Dr. Reddy's lacks sufficient information to determine the total number of patients who may be prescribed its product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; (ii) the current existence of numerous other prescription drugs with the same active pharmaceutical ingredient; and (iii) the existence of numerous other prescriptions drugs to treat these same conditions.
Was the drug granted breakthrough therapy designation by the federal Food and Drug Administration (FDA) prior to final approval?	N
Did the drug receive a priority review by the federal Food and Drug Administration prior to final approval?	N
The date and price of acquisition if the drug was not developed by the manufacturer	NA/NA

Please do not hesitate to contact us if you have any questions.

Regards,

Juan Carlos Alvarez
Government Contracts & Pricing
Dr. Reddy's Laboratories, Inc.